Literature DB >> 14687916

Antithrombin: in control of coagulation.

Noelene S Quinsey1, Ainslie L Greedy, Stephen P Bottomley, James C Whisstock, Robert N Pike.   

Abstract

Antithrombin is a serine proteinase inhibitor (serpin) which controls the process of coagulation. It has a well defined structure, consisting of three beta-sheets, nine alpha-helices and a reactive centre loop (RCL). The RCL contains the reactive centre which harbours a bait sequence for target proteases; cleavage results in inhibition by a unique mechanism. The inhibitory activity of antithrombin is controlled by its interaction with the co-factor, heparin, which accelerates its interaction with target proteases. This ensures that heparin and its newer derivatives, such as heparin pentasaccharide, are the mainstay therapeutics for control of thrombosis or inappropriate clotting. The clinical importance of antithrombin is manifested by its clear association with thrombosis when deficiency states occur.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14687916     DOI: 10.1016/s1357-2725(03)00244-9

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  37 in total

1.  Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.

Authors:  Yao-Hsu Yang; Kwan-Ki Hwang; John FitzGerald; Jennifer M Grossman; Mihaela Taylor; Bevra H Hahn; Pojen P Chen
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Three case reports of inherited antithrombin deficiency in China: double novel missense mutations, a nonsense mutation and a frameshift mutation.

Authors:  Haoyu Deng; Wei Shen; Yi Gu; Xiong Ma; Jiwei Zhang; Lan Zhang
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

Review 3.  The endothelial glycocalyx: composition, functions, and visualization.

Authors:  Sietze Reitsma; Dick W Slaaf; Hans Vink; Marc A M J van Zandvoort; Mirjam G A oude Egbrink
Journal:  Pflugers Arch       Date:  2007-01-26       Impact factor: 3.657

4.  The Rheumatoid Arthritis-Associated Citrullinome.

Authors:  Ronak Tilvawala; Son Hong Nguyen; Aaron J Maurais; Venkatesh V Nemmara; Mitesh Nagar; Ari J Salinger; Sunil Nagpal; Eranthie Weerapana; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2018-04-05       Impact factor: 8.116

5.  Role of the residues of the 39-loop in determining the substrate and inhibitor specificity of factor IXa.

Authors:  Likui Yang; Chandrashekhara Manithody; Shabir H Qureshi; Alireza R Rezaie
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

6.  Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation.

Authors:  Irene Martínez-Martínez; Adriana Ordóñez; José Navarro-Fernández; Angel Pérez-Lara; Ricardo Gutiérrez-Gallego; Rafael Giraldo; Constantino Martínez; Esther Llop; Vicente Vicente; Javier Corral
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

7.  Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation.

Authors:  Bo Rim Kim; Jaeseong Oh; Kyung-Sang Yu; Ho Geol Ryu
Journal:  Br J Clin Pharmacol       Date:  2020-02-18       Impact factor: 4.335

Review 8.  Thrombin inhibitors from different animals.

Authors:  A M Tanaka-Azevedo; K Morais-Zani; R J S Torquato; A S Tanaka
Journal:  J Biomed Biotechnol       Date:  2010-10-04

9.  Recombinant human antithrombin expressed in the milk of non-transgenic goats exhibits high efficiency on rat DIC model.

Authors:  Hai Yang; Qing-Wang Li; Zeng-Sheng Han; Jian-Hong Hu; Wen-Ye Li; Zhi-Bin Liu
Journal:  J Thromb Thrombolysis       Date:  2009-05-20       Impact factor: 2.300

10.  Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.

Authors:  C Erem; M Kocak; A Hacihasanoglu; M Yilmaz
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.